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doi:10.1016/j.fjs.2012.01.001Summary Despite a variety of available medical therapies and electrophysiological interven-
tions, many heart failure patients still have a poor quality of life and a poor prognosis. Cardiac
transplantation is currently the main treatment for end-stage heart failure in Taiwan but it is
sometimes accompanied by rejection, immune compromise, and the adverse side effects of
antirejection drugs. In addition, there is a shortage of donor grafts worldwide. For these
reasons, other surgical interventions that alleviate ischemia and valvular dysfunction, and also
reverse ventricular remodeling, should be considered before transplantation is advised. In this
review, we discuss current nontransplant surgical management strategies for end-stage heart
failure in terms of coronary revascularization, mitral reconstruction, ventricular reconstruc-
tion, and stem-cell regeneration of the myocardium.
Copyright ª 2012, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Despite significant advances in medical therapy such as the
aggressive use of angiotensin-converting enzyme (ACE)
inhibitors and beta-blockers, the main current treatment
modality for congestive heart failure is orthotopic cardiacof Cardiovascular Surgery,
eneral Hospital, 325 Cheng-
n.
mctsgh.edu.tw (C.-S. Tsai).
ight ª 2012, Taiwan Surgical Assotransplantation. Because donor supply is extremely limited,
only 623 heart transplants were performed in Taiwan from
1997 to 2007 according to data from the Bureau of National
Health Insurance, Department of Health, Executive Yuan,
Taiwan R.O.C. Furthermore, data from the Taiwan Organ
Registry And Sharing Center show 84 cases in 2008, 90 in
2009 and 80 in 2010. Nontransplant surgical procedures will
undoubtedly play an important role in the future. In this
review, we discuss nontransplant surgical therapy for end-
stage heart failure. Mechanical circulatory support is
a wide topic and has been purposely excluded from this
review.ciation. Published by Elsevier Taiwan LLC. All rights reserved.
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Ischemic cardiomyopathy is caused by occlusive or
obstructive coronary artery disease. Ischemic cardiomyop-
athy is now recognized as the most common cause of heart
failure worldwide.1e4 It can be described in terms of three
pathophysiological processes. (1) Myocardial hibernation.
This is caused by reduced coronary blood flow that can be
partially or completely restored to normal by myocardial
revascularization. (2) Myocardial stunning. The viable
myocardium is injured by generation of oxygen-derived
free radicals on reperfusion and by a loss of sensitivity of
contractile filaments to calcium. With adequate revascu-
larization, the postischemic contractile dysfunction of the
myocardium can be reversed. (3) Myocardial cell death.
This is an irreversible state and causes ventricular remod-
eling and contractile dysfunction. Myocardial revasculari-
zation can save a jeopardized but still viable myocardium,
but the aims of surgery should be to elicit a significant
improvement in heart failure symptoms, survival rate, and
left ventricular (LV) function. Appraised by means of posi-
tron emission tomography (PET), nuclear thallium studies,
or dobutamine echocardiography tests, the presence of
a hibernating or viable myocardium is essential for
improvement in the left ventricular ejection fraction (LVEF)
after surgical revascularization. Recent studies suggest that
at least 25% of the myocardium should be viable for
revascularization to be successful.5,6 In contrast, there is
no survival benefit to revascularization for patients with no
myocardial viability.7 Current American College of Cardi-
ology/American Heart Association (ACC/AHA) guidelines for
coronary artery bypass graft (CABG) in patients with poor
LV function recommend surgery as a Class I indication for
patients with left main coronary artery disease or its
equivalent as a Class IIa indication for patients with viable
noncontracting muscle, and as a Class III indication for
those without evidence of ischemia or viability.8,9
According to the SHOCK trial (Should We Emergently
Revascularize Occluded Coronaries for Cardiogenic Shock),
for patients with acute myocardial infarction (MI), the 1-
year mortality rate was 42% for CABG, and 56% for medical
therapy alone. Furthermore, for patients in cardiogenic
shock, the 1-year mortality rate was 56% for CABG and 75%
for medical therapy alone.10 Multiple studies have demon-
strated improvements in survival, ventricular function,
and functional status after coronary revascularization in
patients with ischemic cardiomyopathy (LVEF less than
25%).11e13 These series show that the survival rate after
CABG ranges from 85 to 88% after 1 year, from 75 to 82%
after 2 years, from 68 to 80% after 3 years, and from 60 to
80% after 5 years. Operative mortality ranges from 3 to 12%.
Revascularized patients have a better quality of life than
patients treated with medical therapy alone and have
enhanced mobility, peak oxygen consumption, and func-
tional status. After CABG, the incidence of readmission for
congestive heart failure (CHF) is low, and many patients are
able to return to work.11e15 According to the CABG Patch
trial, perioperative mortality was 1.3% in patients without
angina or heart failure. Mortality was 4.8% in patients with
no angina and New York Heart Association (NYHA) Class I or
II heart failure, and 7.4% in patients with no angina andNYHA Class III or IV heart failure.16 Elefteriades and
Edwards reported improvement in LVEF from 23.3 to 33.2%
and improvement in NYHA functional class from 3.1 to
1.4.12 In Meluzin’s prospective study,17 133 patients who
underwent CABG or percutaneous coronary intervention
were randomized into three groups. Group A consisted of 29
patients with a large amount of dysfunctional but viable
myocardium, Group B consisted of 60 patients with a small
amount of dysfunctional but viable myocardium, and Group
C consisted of 44 patients with a dysfunctional and irre-
versibly damaged myocardium. Group A demonstrated the
greatest functional improvement after revascularization,
a lower rate of cardiac events during follow-up (two for
Group A versus 18 for Group B, p < 0.05, and 17 for group C,
p < 0.01), and better cardiac event-free survival according
to KaplaneMeier survival analysis. Another study showed
that revascularization resulted in a 34% increase in exercise
capacity (from 5.6 to 7.5 metabolic equivalents).18
In summary, for patients with ischemic cardiomyopathy,
coronary revascularization should be considered first.
Residual cardiac function and the viability of the myocar-
dium should be assessed using PET, dynamic magnetic
resonance imaging, nuclear thallium studies, or dobut-
amine echocardiography tests. If the amount of viable
myocardium is acceptable, coronary revascularization
should be performed concomitant with mitral or ventricular
reconstruction to prevent progressive ischemia and further
heart failure.3. Mitral reconstruction
Mitral regurgitation (MR) is common in patients with heart
failure and is associated with a poor prognosis. Progressive
LV dilation can result in functional MR secondary to annular
dilation, papillary muscle displacement, or chordal teth-
ering. MR is a risk factor for mortality of nonischemic and
ischemic causes.19 Moreover, MR per se causes LV over-
loading and remodeling, which results in a vicious cycle of
worsening MR.19 The traditional “pop-off valve” hypothesis
stated that surgical correction with mitral valve replace-
ment would be associated with a high mortality rate.
In 1996, Bolling hypothesized that reconstruction of the
mitral valve annulus using an undersized ring would correct
valvular competency, alleviate ventricular workload,
reverse ventricular remodeling, and improve ventricular
function.20 In the past, the high surgical mortality rate
associated with mitral valve replacement was because of
loss of the subvalvular apparatus rather than loss of the
pop-off valve. Maintenance of the integrity of annular and
subvalvular continuity during mitral valve surgery is critical
for survival. Surgical mortality was 5% in Bolling’s study,20
which included 140 Class III and Class IV patients with an
LVEF of less than 25%. The Acorn clinical trial evaluated the
safety and efficacy of mitral valve surgery for advanced
heart failure patients in about 30 different centers. The
operative mortality rate was only 1.6%. The 1-year and
2-year survival rates were 86.5% and 85.2%, respec-
tively.21,22 In Bolling’s study,20 heart failure patients who
underwent mitral valve surgery demonstrated improved
LVEF and decreased end-diastolic volume during 3-year and
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of patients underwent a complete, small annuloplasty
repair. Significant decreases in LV end-diastolic volume, LV
end-systolic volume, and LV mass were observed 2 years
after the procedure, at which time the NYHA class had
decreased from 2.8 to 2.2.
Many randomized trials on ischemic cardiomyopathy
have shown that a coronary artery bypass with mitral valve
repair improves postoperative NYHA functional class and
ventricular remodeling and decreases LV end-diastolic
volume, pulmonary arterial pressure, and hospitalization
for heart failure.23,24 Other studies reported low operative
mortality rates for coronary artery bypass procedures with
mitral annuloplasty in patients with advanced heart failure.
In addition, the combination of surgical revascularization
and mitral valve repair significantly improved the quality of
life of patients with coronary artery and ischemic mitral
insufficiency.25,26
Regarding mitral valve repair in patients with heart
failure, the use of nonflexible rings and downsizing rings are
worthy of mention.23,27 In Spoor’s study,27 the MR recur-
rence rate was 9.5% for the flexible band or ring and only
2.5% for the nonflexible band or ring. The recurrence rates
differ because a nonflexible band or ring enables better
fixation in the septal lateral dimension and thus prevents
annulus dilation. The 2008 guidelines of the ACC/AHA28 and
the 2007 guidelines of the European Society of Cardiology29
recommend mitral annuloplasty with a downsizing ring for
patients with ischemic MR. Most patients with ischemic MR
benefit more from annuloplasty with a rigid downsizing ring
than from annuloplasty with a nondownsizing ring. The
downsizing technique prevents systolic anterior motion in
myopathic patients, probably because of widening of the
aortoemitral angle in hearts with increased left ventricular
size. The geometric restoration afforded by mitral recon-
struction not only effectively corrects MR, but also achieves
surgical unloading of the ventricle.
Finally, two kinds of percutaneous mitral valve repair
system are currently being evaluated. Introduced via
a catheter through the femoral vein and across the atrial
septum, the Edwards Milano II mitral clip (Edwards Life-
sciences, Irvine, CA, USA) and the Evalve Mitraclip system
(Evalve Inc., Menlo Park, CA, USA) create a permanent
coaptation between the leading free edges of the anterior
and posterior mitral leaflets. The EVEREST II trial30 demon-
strated that the procedure is safe and that it improves
clinical outcome to an extent similar to that of conventional
surgery, although it was less effective in reducing MR.
The Viacor percutaneous mitral annuloplasty system
(Viacor Inc., Wilmington, MA, USA) and the Carillon mitral
contour system (Cardiac Dimensions, Kirkland, Washington,
DC, USA) both involve a catheter-based approach to mitral
annuloplasty via the femoral vein and the coronary
sinus.31,32 With these systems, a permanent nitinol strut is
introduced via the femoral vein and the coronary sinus and
wrapped around the posterior annulus of the mitral valve,
reducing the anteroposterior dimension of the mitral
annulus.
In summary, although mitral valve surgery is associated
with a higher mortality rate in patients with advanced heart
failure than in those without heart failure, it restores LV
remodeling, decreases the NYHA functional class, andaffords a better quality of life for patients with ischemic or
idiopathic cardiomyopathies. In the near future, the percu-
taneous mitral valve repair system will be a good choice of
treatment when conventional surgery is contraindicated.4. Geometric ventricular reconstruction
Transmural myocardial infarction may result in ventricular
dilation and remodeling, increasing LV wall stress and LV
dysfunction, which increase myocardial oxygen consumption
and neurohormone and cytokine levels, and cause sub-
endocardial hypoperfusion.33 Moreover, cardiac workload is
increased because of the paradoxical systolic motion of the
infarctedmyocardium, especially when the dyskinetic region
becomes aneurysmal. In the early 1980s, Vincent Dor first
demonstrated the use of endoventricular circular plasty to
maintain a more physiological cavity.34 Other terms have
been used to describe the same or similar procedures, viz.,
endoventricular circular patch plasty repair, surgical
ventricular restoration, left ventricular infarct exclusion
surgery, and left ventricular aneurysmectomy reconstruc-
tion. In principle, geometric ventricular reconstruction
involves isolation of the infarcted areas and subsequent
reduction of left ventricular volumes. Studies conducted
since the work of Dor have also revealed significant
improvement after exclusion of dyskinetic or akinetic
infarcted areas.35e38
The RESTORE multicenter study described various tech-
niques for LV reconstruction in heart failure patients after
myocardial infarction.35 The overall 30-day mortality rate
after surgical ventricular restoration (SVR) was 5.3% (95% of
the patients underwent a concomitant CABG and 22%
underwent concomitant mitral valve repair). The ejection
fraction increased from 29.6% preoperatively to 39.5%
postoperatively. The left ventricular end-systolic volume
index (LVESVI) decreased from 80.4 ml/m2 preoperatively to
56.6 ml/m2 postoperatively. The overall 5-year survival rate
was 68.6%, and the 5-year freedom rate from hospital
readmission for CHF, 78%. Preoperatively, 67% of patients
were NYHA functional Class III or IV and postoperatively,
85% were Class I or II. In the STICH trial, surgical ventricular
reconstruction in combination with CABG reduced the end-
systolic volume index by 19%, as compared with 6% for CABG
alone. Unfortunately, surgical ventricular reconstruction
does not appear to improve symptoms or exercise tolerance
or to reduce the rate of death or hospitalization for cardiac
causes.39 And in the new results of the STITCH trial, patients
assigned to CABG, as compared with those assigned to
medical therapy alone, had lower rates of death from
cardiovascular causes and of death from any other causes
necessitating hospitalization for cardiovascular disorders.40
Other studies have shown improvements in ejection
fraction, NYHA class, and long-term survival after signifi-
cant reductions in the left ventricular end-systolic volume
index.41e45 This procedure is performed regularly and the
associated hospital mortality rate is less than 8% and the
12-month freedom from readmission for CHF rate is greater
than 80%.
With regard to idiopathic end-stage heart failure, Batista
proposed the concept of surgical ventricular remodeling
to optimize wall tension and improve myocardial oxygen
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Laplace.46 Since 1996, he has performed partial left ven-
triculectomy (PLV) in more than 150 cases, predominantly
on patients with Chagas’ disease or dilated cardiomyopathy.
Unfortunately, no meaningful follow-up data or statistical
analyses are available from his series. The Cleveland Clinic
performed partial left ventriculectomy (PLV) on 62 patients
with idiopathic dilated cardiomyopathy. They reported an
operative mortality of 3.5% and a 1-year survival rate of 82%.
However, 24 short-term treatment failures were noted,
including 11 patients who required left ventricular assist
device (VAD) support, six patients who were listed for
transplantation, and seven patients who died without
left VAD support.47 Of these 62 patients, 59 (95%) also
underwent concomitant mitral reconstruction. Because
mitral reconstruction alone could have induced rapid and
complete ventricular remodeling,48 it is difficult to isolate
the role of PLV per se in correction of ventricular remodeling
in the Cleveland Clinic study. At present, there is no defin-
itive evidence for a benefit of PLV in patients with idiopathic
end-stage heart failure.
To optimize Laplace’s law, dynamic cardiomyoplasty
(DCMP) is applied to reduce wall stress by wrapping the
latissimus dorsi muscle around the heart.49,50 The latissimus
dorsi muscle is stimulated to contract in synchrony with the
heart via an electromyostimulator. Because of the absence
of data on hemodynamic or survival improvement, the DCMP
is available only in Russia, Europe, Asia and the Caribbean at
present. The DCMP concept stimulated the development of
passive cardiac support devices, including the Acorn Cardiac
Support Device (ACSD; Acorn Medical, Minneapolis, MN, USA)
and the Myocor Myosplint (Myocor Medical, St Paul, MN,
USA).51e54 The ACSD, which is made of polyester mesh
fabric, is placed outside the ventricles in a posteroanterior
orientation. Similar to the DCMP, the ACSD was proved to
support the dilated ventricles passively, reduce ventricular
wall stress, and prevent further dilation by girdling
compression.55 The Myocor Myosplint directly alters cardiac
geometry and reduces ventricular wall stress.56,57 Under the
hypothesis of optimization of the law of Laplace, the Myocor
Myosplint is placed through the right and left ventricular
walls to achieve a 20% reduction in wall stress. The ACSD and
Myocor Myosplint have been proven to suppress further
ventricular dilation and to improve ejection fraction in
investigational clinical studies. In the future, further studies
will be needed to show the safety and long-term efficacy of
this kind of device.
5. Stem-cell regeneration of myocardium
Stem-cell regeneration of the myocardium, which replaces
myocytes lost from the injured cardiac region, is another
alternative nontransplant treatment for end-stage heart
failure. The myocardium could be regenerated by injecting
stem cells into the damaged heart. The ideal cell types
include skeletal myoblasts, peripheral blood stem cells,
and bone marrow stem cells. The major modes of delivery
consist of direct epicardial injection, percutaneous
catheter-based endocardial injection, and percutaneous
transluminal coronary injection. Possible mechanisms of
myocardial regeneration involve transdifferentiation of stemcells into cardiomyocytes,58e60 cytokine- and growth factor-
mediated endogenous stem cell mobilization, improved
homing of stem cells to sites of injury, and induction of
antiapoptotic pathways.61,62 The paracrine hypothesis has
been emphasized recently.63 Indeed, the ideal stem cell
would secrete a broad variety of cytokines, chemokines and
growth factors that are beneficial for cardiac repair,
providing cytoprotection of resident myocytes, upregulation
of angiogenesis, and modulation of inflammatory process.
And these synergistic effects will promote re-entry of car-
diomyocyte sell cycle, recruit endogenous stem cells, and
induct secondary humoral effects in the host tissue. All the
above-mentioned mechanisms may contribute to neomyo-
genesis, neoangiogenesis, and alteration of ventricular
remodeling. Neomyogenesis results in an overall increase in
functional myocardial mass, whereas the neoangiogenesis
results in increased capillary density, improving myocardial
perfusion and recruiting the hibernating myocardium.
In the early 2000s, Menasche´ et al published a series on
autologous skeletal myoblast transplantation concomitant
with CABG in patients with severe heart failure.64,65 He
demonstrated improvement in NYHA functional class and
left ventricular ejection fraction 11 months after the CABG.
Other studies also showed improved myocardial wall thick-
ening within the injection region and overall improvement
in LVEF.66e68 At the same time as Menasche´’s publications,
Hamano reported autologous bone marrow cell trans-
plantation concomitant with CABG in patients with ischemic
heart disease.69 In 2004, Wollert’s randomized controlled
trial demonstrated the safety and efficacy of bone marrow-
derived cell therapy for acute ST-elevation MI.70 In his
BOOST trial (bone marrow transfer to enhance ST-elevation
infarct regeneration), 60 patients were randomized to
primary percutaneous intervention with or without intra-
coronary infusion of autologous bone marrow cells. At the 6-
month follow-up, the group with cell therapy showed
significant improvement in LVEF (from 50% to 56.7%) as
compared with the group that did not receive cell therapy
(from 51.3% to 52%). Chen’s randomized trial also showed
improvement in LVEF, myocardial perfusion, and wall
motion in acute-MI patients (n Z 69) who underwent
primary percutaneous coronary intervention concomitant
with intracoronary infusion of autologous bone marrow-
derived mesenchymal stem cells.71
In summary, many preclinical and clinical studies
demonstrate that stem cell regeneration of the myocar-
dium is an alternative efficacious treatment for both acute
and chronic myocardial injury. Although therapeutic timing
and specific safety concerns such as ventricular arrhythmia
are always debated, preliminary clinical trials show that
cell therapy has positive benefits. At present, more clinical
trials are needed to clarify several essential details, viz.,
the ideal cell type, cell dose, delivery method, and treat-
ment protocol. In the future, stem-cell regeneration of the
myocardium may become the preferred option in treating
end-stage heart failure.
6. Conclusions
In the past two decades, there has been an expansion of
knowledge on the mechanisms and pathology of remodeling
Management of end-stage heart failure 5in heart failure. In addition to transplantation and the
newly developed mechanical circulatory support tech-
nique, surgical therapy is also an attractive new trend in
management of end-stage heart failure. Together with
optimal medical treatment, these techniques offer patients
with advanced heart failure a better quality of life and
a better prognosis.References
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